Citations

Showing 10 of 108081 citations.

Tris-Hydroxymethyl Aminomethane in Critically Ill Adults: A Systematic Review
Radosevich, Misty A., Wieruszewski, Patrick M. , Wittwer, Erica D. , Wieruszewski, Patrick M

Mayo Clinic

Anesthesia & Analgesia | April 19, 2023 | Volume: 137 | Issue: 5 | Pages: 1007-1018

10.1213/ane.0000000000006485 | PMID 37075790 Get It

Tris-hydroxymethyl aminomethane (THAM) is an amino alcohol used clinically to buffer acid loads and raise pH in acidotic conditions. Unlike sodium bicarbonate, which increases plasma sodium levels with use and produces carbon dioxide (CO 2 ) as part of the buffering process, THAM does neither. Although not widely used in modern critical care and unavailable for clinical use in 2016, THAM has been available in the United States since 2020. Clinical experience and existing literature suggest that THAM may have clinical utility in acid-base management in conditions such as liver transplantation where rising sodium levels during perioperative care may be dangerous, and in managing acid-base derangements during care of patients with acute respiratory distress syndrome (ARDS). To clarify the evidence base supporting the clinical use of THAM, we conducted a systematic review to assess the efficacy and safety of THAM as a buffering agent in critically ill adults using Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus, and Web of Science Core Collection. Randomized-, crossover-, retrospective cohort-, parallel-designed clinical trials, case series, and case reports of adult patients who received THAM in the operative or critical care setting were included. Conference abstracts of qualifying study designs were also included. Two independent reviewers extracted the data regarding the study details, demographics, treatment, and outcomes data. A third reviewer adjudicated discrepancies. A total of 21 studies including 3 randomized controlled trials, 5 observational studies, 4 case series, and 9 case reports met inclusion criteria. Eight studies (38%) were abstracts published in conference proceedings. In total, 417 critically ill patients received THAM to treat acidosis in critically ill surgical and nonsurgical patients, during liver transplantation, and in ARDS. In general, THAM corrected acidosis with an efficacy equivalent to sodium bicarbonate and did so with less hypercarbia and hypernatremia. Adverse effects of THAM included hyperkalemia, hypoglycemia, ventilator depression, and tissue damage with extravasation. We conclude that THAM may have potential advantages in some critical care settings, but that clinical evidence is limited, and high-quality evaluations are necessary.
Neuromuscular ultrasound standardized scanning techniques and protocols: Expert panel recommendations
Tawfik, Eman A. , Cartwright, Michael S. , Alfen, Nens van , Axer, Hubertus , Boon, Andrea J. , Grimm, Alexander , Hobson‐Webb, Lisa D., Kerasnoudis, Antonios , Mandeville, Ross , Preston, David C. , Sakamuri, Sarada, Shin, Susan , Shook, Steven J. , Walker, Francis O. , van Alfen, Nens , Crump, Nicholas , Kerasnoudis, Antonios , Preston, David C , Shin, Susan , Crump, Nicholas , Shahrizaila, Nortina , Wilder‐Smith, Einar

Mayo Clinic

Muscle & Nerve | April 19, 2023 | Volume: 68 | Issue: 4 | Pages: 375-379

10.1002/mus.27830 | PMID 37074101 Get It

AbstractNeuromuscular ultrasound has become an integral part of the diagnostic workup of neuromuscular disorders at many centers. Despite its growing utility, uniform standard scanning techniques do not currently exist. Scanning approaches for similar diseases vary in the literature creating heterogeneity in the studies as reported in several meta‐analysis. Moreover, neuromuscular ultrasound experts including the group in this study have different views with regards to technical aspects, scanning protocols, and the parameters that should be assessed. Establishing standardized neuromuscular scanning protocols is essential for the development of the subspeciality to ensure uniform clinical and research practices. Therefore, we aimed to recommend consensus‐based standardized scanning techniques and protocols for common neuromuscular disorders using the Delphi approach. A panel of 17 experts participated in the study, which consisted of three consecutive electronic surveys. The first survey included voting on six scanning protocols addressing the general scanning technique and five common categories of suspected neuromuscular disorders. The subsequent surveys focused on refining the protocols and voting on new steps, rephrased statements, or areas of non‐agreement. A high degree of consensus was achieved on the general neuromuscular ultrasound scanning technique and the scanning protocols for focal mononeuropathies, brachial plexopathies, polyneuropathies, amyotophic lateral sclerosis, and muscle diseases. In this study, a group of neuromuscular ultrasound experts developed six consensus‐based neuromuscular ultrasound scanning protocols that may serve as references for clinicians and researchers. The standardized protocols could also aid in achieving high‐quality uniform neuromuscular ultrasound practices.
Artificial Intelligence for the Detection and Treatment of Atrial Fibrillation
Harmon, David , Sehrawat, Ojasav , Maanja, Maren , Wight, John , Noseworthy, Peter A. , Harmon, David M , Noseworthy, Peter A

Mayo Clinic

Arrhythmia & Electrophysiology Review | April 19, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.15420/aer.2022.31 | PMID 37427304 Get It

AF is the most common clinically relevant cardiac arrhythmia associated with multiple comorbidities, cardiovascular complications (e.g. stroke) and increased mortality. As artificial intelligence (AI) continues to transform the practice of medicine, this review article highlights specific applications of AI for the screening, diagnosis and treatment of AF. Routinely used digital devices and diagnostic technology have been significantly enhanced by these AI algorithms, increasing the potential for large-scale population-based screening and improved diagnostic assessments. These technologies have similarly impacted the treatment pathway of AF, identifying patients who may benefit from specific therapeutic interventions. While the application of AI to the diagnostic and therapeutic pathway of AF has been tremendously successful, the pitfalls and limitations of these algorithms must be thoroughly considered. Overall, the multifaceted applications of AI for AF are a hallmark of this emerging era of medicine.
Navigating Practice Issues Related to the Unsatisfactory Cervicovaginal Papanicolaou Test: Survey Results of Laboratories Participating in the 2020 College of American Pathologists PAP Education Program
Booth, Christine N. , Souers, Rhona J., Tabbara, Sana, Roberson, Janie, Henry, Michael , Sundling, Kaitlin E. , Goodrich, Kelly, Henry, Michael R, Goyal, Abha , Nguyen, Lananh

Mayo Clinic

Archives of Pathology & Laboratory Medicine | April 19, 2023 | Volume: 148 | Issue: 1 | Pages: 48-54

10.5858/arpa.2022-0330-cp | PMID 37074866 Get It

Context.— Unsatisfactory Papanicolaou (Pap) tests pose a unique set of challenges to the laboratory with regard to their processing, review, reporting, and performance of human papillomavirus (HPV) testing. There are no standardized guidelines for the review process and handling of unsatisfactory Pap tests. Objective.— To assess the current practice patterns regarding various aspects of the unsatisfactory Pap test, from processing to reporting, across laboratories worldwide. Design.— A supplemental questionnaire was mailed to laboratories participating in the 2020 College of American Pathologists (CAP) Gynecologic Cytopathology (PAP Education) Program, requesting data regarding the unsatisfactory Pap test. Results.— Of 1520 participating laboratories, 619 (40.7%) responded, and the responses of 577 laboratories were included for further analysis. Only 64.6% (373 of 577) laboratories used the unsatisfactory Pap test criteria as specified by the 2014 Bethesda System. About three-quarters of the respondents (433 of 576; 75.2%) routinely rescreened unsatisfactory Pap tests. Routine repreparation of such Pap tests was performed by 54.9% (316 of 576) of laboratories, and 52.0% (293 of 563) used glacial acetic acid for repreparing excessively bloody specimens. HPV test results were reported for unsatisfactory Pap tests, always or sometimes, by 62.4% (353 of 566) of respondents. Conclusions.— This CAP survey reveals important information regarding the practice patterns pertaining to several aspects of the unsatisfactory Pap test. It also provides valuable insight into the quality assurance measures that can be implemented for such tests. Future studies can further aid in the standardization of all components of the handling of unsatisfactory Pap tests for overall quality improvement.
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Ailawadhi, Sikander , Chen, Zi , Huang, Bo , Paulus, Aneel , Collins, Mary C. , Fu, Lei , Li, Mingyu , Ahmad, Mohammad , Men, Lichuang , Wang, Hengbang , Liang, Eric , Mekala, Divya J. , He, Zhicong , Lasica, Masa , Yannakou, Costas K. , Glass, Laura , Yang, Dajun , Chanan‐Khan, Asher , Fu, Lei Tommy , Davids, Matthew S , Liang, Eric , Mekala, Divya J , He, Zhicong , Lasica, Masa , Yannakou, Costas K , Parrondo, Ricardo D , Glass, Laura , Yang, Dajun , Chanan-Khan, Asher , Zhai, Yifan , Ailawadhi, Sikander , Paulus, Aneel , Davids, Matthew S.

Mayo Clinic

Clinical Cancer Research | April 19, 2023 | Volume: 29 | Issue: 13 | Pages: 2385-2393

10.1158/1078-0432.ccr-22-3321 | PMID 37074726 Get It

Abstract Purpose: This global phase I trial investigated the safety, efficacy, pharmacokinetics, and pharmacodynamics of lisaftoclax (APG-2575), a novel, orally active, potent selective B-cell lymphoma 2 (BCL-2) inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL) and other hematologic malignancies (HMs). Patients and Methods: Maximum tolerated dose (MTD) and recommended phase II dose were evaluated. Outcome measures were safety and tolerability (primary) and pharmacokinetic variables and antitumor effects (secondary). Pharmacodynamics in patient tumor cells were explored. Results: Among 52 patients receiving lisaftoclax, MTD was not reached. Treatment-emergent adverse events (TEAEs) included diarrhea (48.1%), fatigue (34.6%), nausea (30.8%), anemia and thrombocytopenia (28.8% each), neutropenia (26.9%), constipation (25.0%), vomiting (23.1%), headache (21.2%), peripheral edema and hypokalemia (17.3% each), and arthralgia (15.4%). Grade ≥ 3 hematologic TEAEs included neutropenia (21.2%), thrombocytopenia (13.5%), and anemia (9.6%), none resulting in treatment discontinuation. Clinical pharmacokinetic and pharmacodynamic results demonstrated that lisaftoclax had a limited plasma residence and systemic exposure and elicited rapid clearance of malignant cells. With a median treatment of 15 (range, 6–43) cycles, 14 of 22 efficacy-evaluable patients with R/R CLL/SLL experienced partial responses, for an objective response rate of 63.6% and median time to response of 2 (range, 2–8) cycles. Conclusions: Lisaftoclax was well tolerated, with no evidence of tumor lysis syndrome. Dose-limiting toxicity was not reached at the highest dose level. Lisaftoclax has a unique pharmacokinetic profile compatible with a potentially more convenient daily (vs. weekly) dose ramp-up schedule and induced rapid clinical responses in patients with CLL/SLL, warranting continued clinical investigation.
Cervical Radiofrequency Ablation Artifact Mimicking an Electrographic Seizure on RNS
Sánchez, Sofía S. , Freund, Brin , Khan, Aafreen , Middlebrooks, Erik H. , Tatum, William O. , Feyissa, Anteneh M. , Middlebrooks, Erik H , Sanchez-Boluarte, Sofia S , Grewal, Sanjeet S.

Mayo Clinic

Journal of Clinical Neurophysiology | April 19, 2023 | Volume: 40 | Issue: 5 | Pages: 478-480

10.1097/wnp.0000000000000989 | PMID 37074333 Get It

Summary: The responsive neurostimulator continuously monitors the electrocorticogram. It delivers short bursts of high-frequency electrical stimulation when personalized patterns are detected. Intracranial EEG recording including electrocorticography is susceptible to artifacts, albeit at a lesser frequency compared with scalp recording. The authors describe a novel case of a patient with focal epilepsy, bitemporal responsive neurostimulation, and seizures without self-awareness manifest as focal impaired awareness seizures adversely affecting memory. At follow-up evaluation, the patient reported being clinically seizure-free although a single long episode was detected using the Patient Data Management System over the course of 3 years. Initial review identified a left-sided rhythmic discharge with a bilateral spatial field of involvement. In response to detection, the responsive neurostimulation delivered a series of five electrical stimulations. On further review, the patient recalled undergoing cervical radiofrequency ablation, which coincided with the appearance of the “electrographic seizure.” Extrinsic electrical artifact involving monomorphic nonevolving waveforms confirmed electrical artifact identified and treated by responsive neurostimulation as an epileptic seizure. On rare occasion, implanted electrical devices may lead to misdiagnosis and mistreatment of patients because of intracranial artifact.
Scapulothoracic Fusion Using Multiple Suture Tape Cerclage
Ba, Papa Amadou, Werthel, Jean-David , Schoch, Bradley, Schoch, Bradley S.

Mayo Clinic

Techniques in Hand & Upper Extremity Surgery | April 19, 2023 | Volume: 27 | Issue: 3 | Pages: 175-181

10.1097/bth.0000000000000434 | PMID 37073680 Get It

Abstract: Scapulothoracic arthrodesis has been proposed for the treatment of painful scapular winging in patients with facioscapulohumeral muscular dystrophy. It was introduced to improve shoulder function. Several methods of fixation have been proposed to obtain the union of the scapula to the ribs. These include plates, screws, cables, or wires with or without bone grafting. The purpose of this manuscript is to describe the surgical technique of scapulothoracic arthrodesis using plate and cerclage suture tapes. Level of Evidence: Level IV, treatment study (case series).
Cancer recurrence or aggravation following COVID-19 vaccination
Soleimani, Parisa , Yadollahifarsani, Sepideh , Motieian, Mahsa , Moghadam, Mahshid Sadat Chenarani , Alimohammadi, Shahrzad , Khayyat, Azadeh , Pour, Mohammad Ali Esmaeil , Neshat, Sina , Marashi, Narges Alsadat , Mahmoodnia, Leila , Masomi, Rohollah

Mayo Clinic

Journal of Nephropharmacology | April 19, 2023 | Volume: 12 | Issue: 2 | Pages: e10593

10.34172/npj.2023.10593 Get It

COVID-19 infection has been a global health issue in the past recent years and numerous topics are studied in order to discover its pathophysiology and potential side effects. The potential for disease recurrence following the administration of the COVID-19 vaccine is one of the issues that has recently attracted attention. Several studies have revealed that the COVID-19 vaccines, like other vaccines, may have side effects and, in some cases, they may even deteriorate the underlying illnesses, such as rheumatic diseases, autoimmune diseases, and cancers. The effectiveness and safety of the COVID-19 vaccine for patients with malignancies are one of the factors that are considered regarding this vaccine. Lymph node involvement, disease recurrence, and potential paraclinical changes after receiving the COVID-19 vaccine are some of the concerns of patients with malignancy. In this mini-review, we attempted to investigate cases of cancer recurrence or recovery as well as lymphadenopathy following vaccination.
Focal versus craniospinal radiation for disseminated atypical teratoid/rhabdoid tumor following favorable response to systemic therapy
Aridgides, Paul , Mahajan, Anita , Eaton, Bree R. , Timmerman, Beate, Früwald, Michael C., Nemes, Karolina , Deck, Jared , Yamasaki, Kai , Hoff, Katja von , Lafay‐Cousin, Lucie , Reddy, Alyssa , Aridgides, Paul D , Eaton, Bree , Deck, Jared , Yamasaki, Kai , Hodgson, David C , Von Hoff, Katja , Wang, Dongliang , Hodgson, David C.

Mayo Clinic

Pediatric Blood & Cancer | April 19, 2023 | Volume: 70 | Issue: 7 | Pages: No page available

10.1002/pbc.30351 | PMID 37073482 Get It

AbstractPurposeRadiotherapy (RT) is associated with improved survival in atypical teratoid/rhabdoid tumor (ATRT); however, optimal RT delivery is unknown. A meta‐analysis was conducted for disseminated (M+) ATRT receiving focal or craniospinal radiation (CSI).MethodsAfter abstract screening, 25 studies (1995–2020) contained necessary patient, disease, and radiation treatment information (N = 96). All abstract, full text, and data capture were independently double‐reviewed. The corresponding author was contacted for cases of insufficient information. Response to pre‐radiation chemotherapy (N = 57) was categorized as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Univariate and multivariate statistics were performed to investigate survival correlation. Patients with M4 disease were excluded.ResultsThe 2‐ and 4‐year overall survival (OS) was 63.8% and 45.7%, respectively, with a median follow‐up of 2 years (range 0.3–13.5). The median age was 2 years (range 0.2–19.5), and 96% received chemotherapy. On univariate analysis, gross total resection (GTR, p = .0007), pre‐radiation chemotherapy response (p < .001), and high‐dose chemotherapy with stem cell recuse (HDSCT, p = .002) correlated with survival. On multivariate analysis, pre‐radiation chemotherapy response (p = .02) and GTR (p = .012) retained survival significance as compared to a trend for HDSCT (p = .072). Comparisons of focal RT (vs. CSI) and greater than or equal to 5400 cGy primary dose were nonsignificant. Following CR or PR, a statistical trend favored focal radiation (p = .089) over CSI.ConclusionChemotherapy response prior to RT and GTR correlated with improved survival on multivariate analysis for ATRT M+ receiving RT. No benefit was observed for CSI compared to focal RT among all patients and following favorable chemotherapy response, inviting further study of focal RT for ATRT M+.
Self-Triage Use, Subsequent Healthcare Utilization, and Diagnoses: A Retrospective Study of Process and Clinical Outcomes Following Self-Triage and Self-Scheduling for Ear or Hearing Symptoms
North, Frederick , Jensen, Teresa B. , Stroebel, Robert J. , Nelson, Elissa M , Johnson, Brenda J , Thompson, Matthew C , Pecina, Jennifer L. , Crum, Brian A. , Pecina, Jennifer , Crum, Brian A , Thompson, Matthew C

Mayo Clinic

Health Services Research and Managerial Epidemiology | April 19, 2023 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/23333928231168121 | PMID 37101803 Get It

Background Self-triage is becoming more widespread, but little is known about the people who are using online self-triage tools and their outcomes. For self-triage researchers, there are significant barriers to capturing subsequent healthcare outcomes. Our integrated healthcare system was able to capture subsequent healthcare utilization of individuals who used self-triage integrated with self-scheduling of provider visits. Methods We retrospectively examined healthcare utilization and diagnoses after patients had used self-triage and self-scheduling for ear or hearing symptoms. Outcomes and counts of office visits, telemedicine interactions, emergency department visits, and hospitalizations were captured. Diagnosis codes associated with subsequent provider visits were dichotomously categorized as being associated with ear or hearing concerns or not. Nonvisit care encounters of patient-initiated messages, nurse triage calls, and clinical communications were also captured. Results For 2168 self-triage uses, we were able to capture subsequent healthcare encounters within 7 days of the self-triage for 80.5% (1745/2168). In subsequent 1092 office visits with diagnoses, 83.1% (891/1092) of the uses were associated with relevant ear, nose and throat diagnoses. Only 0.24% (4/1662) of patients with captured outcomes were associated with a hospitalization within 7 days. Self-triage resulted in a self-scheduled office visit in 7.2% (126/1745). Office visits resulting from a self-scheduled visit had significantly fewer combined non-visit care encounters per office visit (fewer combined nurse triage calls, patient messages, and clinical communication messages) than office visits that were not self-scheduled (−0.51; 95% CI, −0.72 to −0.29; P < .0001). Conclusion In an appropriate healthcare setting, self-triage outcomes can be captured in a high percentage of uses to examine for safety, patient adherence to recommendations, and efficiency of self-triage. With the ear or hearing self-triage, most uses had subsequent visit diagnoses relevant to ear or hearing, so most patients appeared to be selecting the appropriate self-triage pathway for their symptoms.